• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Detection of anti-BP180 NC16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid: a report of three patients.

作者信息

Mai Y, Nishie W, Izumi K, Yoshimoto N, Morita Y, Watanabe M, Toyonaga E, Ujiie H, Iwata H, Fujita Y, Nomura T, Sato-Matsumura K C, Shimizu S, Shimizu H

机构信息

Department of Dermatology, Hokkaido University Graduate School of Medicine, North 15 West 7, Kita-ku, Sapporo, 060-8638, Japan.

Department of Dermatology, JR Sapporo Hospital, Sapporo, Japan.

出版信息

Br J Dermatol. 2018 Sep;179(3):790-791. doi: 10.1111/bjd.16656. Epub 2018 Jun 25.

DOI:10.1111/bjd.16656
PMID:29624639
Abstract
摘要

相似文献

1
Detection of anti-BP180 NC16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid: a report of three patients.二肽基肽酶-IV抑制剂相关大疱性类天疱疮发病后抗BP180 NC16A自身抗体的检测:三例报告
Br J Dermatol. 2018 Sep;179(3):790-791. doi: 10.1111/bjd.16656. Epub 2018 Jun 25.
2
Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.二肽基肽酶-4 抑制剂相关性大疱性类天疱疮自身抗体对 BP180 细胞外结构域的优先反应性。
Front Immunol. 2019 May 29;10:1224. doi: 10.3389/fimmu.2019.01224. eCollection 2019.
3
More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study.尽管二肽基肽酶-4 抑制剂(DPP4i)相关大疱性类天疱疮患者的循环自身抗体水平较低,但仍存在更严重的侵蚀性表型:一项回顾性队列研究。
Am J Clin Dermatol. 2021 Jan;22(1):117-127. doi: 10.1007/s40257-020-00563-7.
4
Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics.二肽基肽酶IV抑制剂相关的大疱性类天疱疮:一种最近被认识的具有独特临床、免疫学和遗传学特征的自身免疫性大疱病。
Immunol Med. 2019 Mar;42(1):22-28. doi: 10.1080/25785826.2019.1619233. Epub 2019 Jun 6.
5
Lichen planus pemphigoides developing from patient with non-small-cell lung cancer treated with nivolumab.一名接受纳武单抗治疗的非小细胞肺癌患者发生了类天疱疮样扁平苔藓。
J Dermatol. 2019 Oct;46(10):e374-e375. doi: 10.1111/1346-8138.14906. Epub 2019 May 7.
6
Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.二肽基肽酶-4 抑制剂相关性大疱性类天疱疮患者皮肤中嗜酸性粒细胞浸润减少。
J Dermatol. 2018 May;45(5):596-599. doi: 10.1111/1346-8138.14245. Epub 2018 Feb 6.
7
Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.二肽基肽酶-4 抑制剂诱导的大疱性类天疱疮。八例临床和免疫学特征。
Int J Dermatol. 2018 Jul;57(7):810-816. doi: 10.1111/ijd.14005. Epub 2018 Apr 23.
8
Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid showing positive autoantibody responses to multiple epitopes.对多种表位呈现自身抗体阳性反应的二肽基肽酶-4抑制剂相关大疱性类天疱疮
J Dermatol Sci. 2021 Sep;103(3):190-192. doi: 10.1016/j.jdermsci.2021.08.004. Epub 2021 Aug 20.
9
Βullous pemphigoid in patients with DPP-4 inhibitors at the onset of disease: does this differ from common bullous pemphigoid?疾病初发时使用二肽基肽酶-4抑制剂的患者发生大疱性类天疱疮:这与普通大疱性类天疱疮有差异吗?
Eur J Dermatol. 2018 Oct 1;28(5):711-713. doi: 10.1684/ejd.2018.3371.
10
Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis.二肽基肽酶-4 抑制剂相关性大疱性类天疱疮患者合并获得性反应性穿孔性胶原病。
J Dermatol. 2018 May;45(5):600-602. doi: 10.1111/1346-8138.14254. Epub 2018 Feb 14.

引用本文的文献

1
Identification of distinct epitopes in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.二肽基肽酶-4抑制剂相关大疱性类天疱疮中不同表位的鉴定
Sci Adv. 2025 Aug;11(31):eadv9423. doi: 10.1126/sciadv.adv9423. Epub 2025 Aug 1.
2
New-onset or flare-up of bullous pemphigoid associated with COVID-19 vaccines: a systematic review of case report and case series studies.与新冠病毒疫苗相关的大疱性类天疱疮新发或复发:病例报告和病例系列研究的系统评价
Front Med (Lausanne). 2024 Apr 8;11:1293920. doi: 10.3389/fmed.2024.1293920. eCollection 2024.
3
From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid.
从药物相关性大疱性表皮松解症的分子见解到临床观点。
Int J Mol Sci. 2023 Nov 26;24(23):16786. doi: 10.3390/ijms242316786.
4
Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin.二肽基肽酶-4 抑制剂治疗的糖尿病患者并发大疱性类天疱疮:硬币的另一面。
J Transl Med. 2021 Dec 20;19(1):520. doi: 10.1186/s12967-021-03192-8.
5
Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid.二肽基肽酶-4抑制剂相关非炎症性大疱性类天疱疮的临床、实验室及组织学特征
J Clin Med. 2021 Apr 28;10(9):1916. doi: 10.3390/jcm10091916.
6
Bullous Pemphigoid: Trigger and Predisposing Factors.大疱性类天疱疮:触发因素和易感因素。
Biomolecules. 2020 Oct 10;10(10):1432. doi: 10.3390/biom10101432.
7
Immune Reaction to Type XVII Collagen Induces Intramolecular and Intermolecular Epitope Spreading in Experimental Bullous Pemphigoid Models.免疫反应对 XVII 型胶原诱导实验性大疱性类天疱疮模型中的分子内和分子间表位扩展。
Front Immunol. 2019 Jun 19;10:1410. doi: 10.3389/fimmu.2019.01410. eCollection 2019.
8
Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.二肽基肽酶-4 抑制剂相关性大疱性类天疱疮。
Front Immunol. 2019 Jun 4;10:1238. doi: 10.3389/fimmu.2019.01238. eCollection 2019.
9
Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.二肽基肽酶-4 抑制剂相关性大疱性类天疱疮自身抗体对 BP180 细胞外结构域的优先反应性。
Front Immunol. 2019 May 29;10:1224. doi: 10.3389/fimmu.2019.01224. eCollection 2019.